Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies

NCT03088878 is registered in ClinicalTrials.gov with Oncternal Therapeutics, Inc as lead sponsor.

NCT NCT03088878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03088878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Lead sponsor
Oncternal Therapeutics, Inc
Phase
Phase 1/2
Overall status
Completed
Start date
January 3, 2018
Completion date
September 25, 2024
Enrollment
95 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma